SCHEMBL6891833

SCHEMBL6891833

CS(=O)(=O)N1CCN(Cc2cc(N)n3ncc(-c4cnc5ccccc5c4)c3n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 15/20 0.42
PIK3R1 P27986 12/20 0.42
MTOR P42345 6/20 0.42
PIK3CD O00329 5/20 0.42
PIK3CB P42338 5/20 0.42
PIK3CG P48736 5/20 0.42
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893473 0.88 KDM4E (0.42) PIK3CAMTORKDM4EMEN1NPC1
SCHEMBL6894410 0.84 KDM4E (0.41) PIK3CAMTORKDM4EMEN1NPC1
SCHEMBL584529 0.84 HSP90AA1 (0.45) PIK3CAMTORPIK3CDKDM4EMEN1
SCHEMBL6893056 0.84 KDM4E (0.40) PIK3CAKDM4EMEN1NPC1ALDH1A1
SCHEMBL6891839 0.83 CHEK1 (0.43) PIK3CAPIK3R1MTORPIK3CDPIK3CB
SCHEMBL7883143 0.83 KDM4E (0.40) PIK3CAMTORKDM4EMEN1NPC1
SCHEMBL6893328 0.82 PIK3CA (0.40) PIK3CAMTORKDM4EMEN1NPC1
SCHEMBL6892777 0.81 HSP90AA1 (0.44) PIK3CAMTORPIK3CDKDM4EMEN1
SCHEMBL6895960 0.79 EGFR (0.38) PIK3CAMTOR
SCHEMBL6894412 0.78 PIK3CA (0.35) PIK3CAMTORKDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 PIK3CA 2681/4885PIK3R1 2651/4885MTOR 1824/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR PIK3CA 34/4885PIK3R1 333/4885MTOR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.